טוען...
Treatment compliance with first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study
Introduction: Non-adherence to disease-modifying therapies (DMTs) in multiple sclerosis may be associated with reduced efficacy. We assessed compliance, the reasons for non-compliance, treatment satisfaction, and quality of life (QoL) of patients treated with first-line therapies. Methods: A cross-s...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier España
2015-05-01
|
| סדרה: | Neurología (English Edition) |
| גישה מקוונת: | http://www.sciencedirect.com/science/article/pii/S2173580815000346 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|